-
Innovation Ranking
Innovation Ranking – Blueprint Medicines Corp
Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, is precision therapy company that inventing medicines for people with cancer and blood disorders. The company product pipeline includes AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST) and GAVRETO (pralsetinib) against non-small cell lung cancer in adults, BLU-263 targeting indolent systemic mastocytosis. It also offer GAVRETO, BLU-701, BLU-945, BLU-451, BLU-222 and BLU-852. Blueprint Medicines is advancing pralsetinib inhibitor against RET (Ret Proto-Oncogene) modified medullary thyroid carcinoma and other solid tumors...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fisogatinib in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fisogatinib in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fisogatinib in Hepatocellular Carcinoma Drug Details: Fisogatinib (BLU-554) is under development...
-
Product Insights
NewAgendia NV Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Agendia NV Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Agendia NV (Agendia) is a molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products. The company discovers, develops and commercializes products for the treatment of cancer. Its products comprise mammaprint, blueprint, targetprint, coloprint, theraprint for breast cancer, theraprint for colon cancer, and symphony, and among others. Agendia product MammaPrint provides individualized metastasis risk assessment of breast cancer patients....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pralsetinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pralsetinib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pralsetinib in Solid Tumor Drug Details: Pralsetinib (Gavreto) is an anticancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avapritinib in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avapritinib in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Avapritinib in Refractory Acute Myeloid Leukemia Drug Details: Avapritinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avapritinib in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avapritinib in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Avapritinib in Relapsed Acute Myeloid Leukemia Drug Details: Avapritinib...
-
Product Insights
NewNet Present Value Model: Novartis AG’s Peptide to Antagonize GRPR for Oncology
Empower your strategies with our Net Present Value Model: Novartis AG's Peptide to Antagonize GRPR for Oncology report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Vertex Pharmaceuticals Inc’s VX-548
Empower your strategies with our Net Present Value Model: Vertex Pharmaceuticals Inc's VX-548 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Sector Analysis
Thailand Renewable Energy Policy Handbook, 2024 Update
Thailand Renewable Energy Policy Overview Thailand’s energy policies are prepared and proposed by the Ministry of Energy (MoE) through the Energy Policy and Planning Office, which also includes the National Energy Policy Council (NEPC). The Energy Regulatory Commission regulates policies related to electric power and natural gas transmission. "Thailand Renewable Energy Policy Handbook 2024” is among the latest country-specific policy reports from GlobalData, the industry analysis specialist. The report offers comprehensive information on major policies governing the renewable energy market...